Synopsis of recent research by authors named "Karen McAdam"
* Notable findings include the PARTNER trial, which investigated the addition of olaparib to chemotherapy for triple-negative breast cancer, and the ARISTACAT trial, which assessed the impact of Src inhibition on oestrogen resistance in hormone-sensitive metastatic breast cancer.
* Her studies underscore the importance of treatment duration, as seen in the PERSEPHONE trial, which highlighted that 6 months of adjuvant trastuzumab is non-inferior to the standard 12-month treatment, potentially reducing toxicity and healthcare costs while maintaining efficacy for HER2-positive early breast cancer patients.*